7 recruiting, 6 completed, 1 not yet recruiting, 1 unknown. 7 Phase 1, 7 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 4, Recruiting 2, Unknown 1 |
| Phase 2 | 7 | Recruiting 4, Completed 2, Not yet recruiting 1 |
| Phase 3 | 3 | Recruiting 3 |
Follow BeBetter Med Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL) Ifupinostat Hydrochloride for Injection, Cyclophosphamide for Injection, Doxorubicin Hydrochloride for Injection - Previously Untreated Peripheral T-Cell Lymphoma | Phase 2 | Not yet recruiting | BeBetter Med Inc | 120 | 2026-07-01 | 2026-06-30 |
| A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer BEBT-209 capsules, Carboplatin Injection, Gemcitabine Hydrochloride for Injection - Locally Advanced Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer | Phase 2 / Phase 3 | Recruiting | BeBetter Med Inc | 446 | 2026-06-04 | 2026-08-18 |
| A Study of BEBT-701 in Patients With Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol（LDL-C） BEBT-701 Injection, BEBT-701 Injection Placebo（0.9% Sodium Chloride Injection） - Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol | Phase 1 / Phase 2 | Recruiting | BeBetter Med Inc | 340 | 2026-03-01 | 2026-08-18 |
| Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV) BEBT-507 Injection - Polycythemia Vera | Phase 1 | Recruiting | BeBetter Med Inc | 90 | 2025-06-17 | 2026-08-18 |
| Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ifupinostat Hydrochloride for Injection, Rituximab Injection, Gemcitabine Hydrochloride for Injection - Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | BeBetter Med Inc | 416 | 2025-01-06 | 2026-08-19 |
| Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations BEBT-109 Capsules, Pemetrexed Disodium for Injection, Carboplatin Injection - Non Small Cell Lung Cancer | Phase 2 | Recruiting | BeBetter Med Inc | 30 | 2024-08-28 | 2026-08-18 |
| Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma BEBT-908 for Injection, Rituximab Injection, Gemcitabine Hydrochloride for Injection - Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Unknown | BeBetter Med Inc | 75 | 2023-12-01 | 2023-12-11 |
| Study of BEBT-607 Tablets in The Treatment of Advanced or Metastatic Solid Tumors With KRAS G12C Mutation BEBT-607Tablets - Advanced or Metastatic Solid Tumor, KRAS G12C Mutation | Phase 1 | Completed | BeBetter Med Inc | 11 | 2023-09-18 | 2026-08-18 |
| A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer BEBT-209 capsules, Carboplatin injection, Gemcitabine hydrochloride for injection - Advanced Triple-Negative Breast Cancer | Phase 2 | Completed | BeBetter Med Inc | 65 | 2023-04-12 | 2026-08-18 |
| Study of Orally Administered BEBT-503 in Healthy Subjects BEBT-503 20mg, BEBT-503 40mg, BEBT-503 80mg - Healthy Subjects | Phase 1 | Completed | BeBetter Med Inc | 57 | 2022-08-26 | 2023-09-18 |
| Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy BEBT-209 capsules, BEBT-209 Placebo capluses, Fulvestrant Injection - HR+/HER2- Locally Advanced, Metastatic Breast Cancer | Phase 3 | Recruiting | BeBetter Med Inc | 330 | 2022-06-09 | 2025-05-31 |
| Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer BEBT-109 Capsule - Non-Small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation | Phase 2 | Recruiting | BeBetter Med Inc | 200 | 2022-04-15 | 2024-11-26 |
| Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects BEBT-908 for injection - Relapsed or Refractory Diffuse Large B-cell Lymphoma | Phase 2 | Completed | BeBetter Med Inc | 128 | 2020-06-12 | 2026-08-18 |
| Phase I Study of BEBT-209 in Women With Advanced Breast Cancer BEBT-209 capsules, Letrozole tablets, Fulvestrant - Advanced Breast Cancer | Phase 1 | Completed | BeBetter Med Inc | 100 | 2019-07-15 | 2026-08-18 |
| Study of BEBT-908 in Subjects With Advanced Hematological Tumors BEBT-908 for injection - Relapsed or Refractory Non-Hodgkin's Lymphoma, Relapsed or Refractory Multiple Myeloma | Phase 1 | Completed | BeBetter Med Inc | 32 | 2016-03-02 | 2023-10-13 |
Lymphoma, Large B-Cell, Diffuse (3) · Carcinoma, Non-Small-Cell Lung (2) · Recurrence (2) · Breast Neoplasms (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Neoplasm Metastasis (1) · Polycythemia Vera (1) · Triple Negative Breast Neoplasms (1)
Injections (8) · BEBT-908 (5) · Carboplatin (5) · Gemcitabine (4) · Etoposide (2) · Fulvestrant (2) · Ifosfamide (2) · Oxaliplatin (2) · Rituximab (2) · Cisplatin (1) · Cyclophosphamide (1) · Doxorubicin (1) · Letrozole (1) · Pemetrexed (1) · Prednisone (1)
China (14) · Australia (1)
Yuankai Shi, Phd (3) · Quchang Ouyang, Phd (2) · Binghe Xu, Ph.D (1) · Guoping Yang, Ph.D (1) · Heli Liu, Ph.D (1) · Hong Yuan, Ph.D (1) · Hongyan Tong, Ph.D (1) · Hui Zhou, Phd (1) · Jason Lickliter, CMO (1) · Li Zhang, Master (1) · Nong Yang, Phd (1) · Qiang Liu, PhD (1) · Qiang Liu, Phd (1) · Quchang Ouyang, PhD (1) · Shouman Wang, Phd (1)